Q1 Earnings Forecast for ADAP Issued By HC Wainwright

Adaptimmune Therapeutics plc (NASDAQ:ADAP) – HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Adaptimmune Therapeutics in a research note issued on Thursday, November 14th. HC Wainwright analyst A. He anticipates that the biotechnology company will earn ($0.18) per share for the quarter. HC Wainwright has a “Buy” rating and a $3.50 price objective on the stock. The consensus estimate for Adaptimmune Therapeutics’ current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Adaptimmune Therapeutics’ Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.12) EPS and Q4 2025 earnings at ($0.12) EPS.

Several other equities analysts have also issued reports on ADAP. StockNews.com lowered Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Guggenheim reduced their price objective on shares of Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research note on Friday. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $3.16.

Adaptimmune Therapeutics Stock Performance

ADAP opened at $0.59 on Friday. The company has a current ratio of 3.09, a quick ratio of 3.09 and a debt-to-equity ratio of 0.26. The firm has a market cap of $150.02 million, a price-to-earnings ratio of -2.67 and a beta of 2.26. Adaptimmune Therapeutics has a 12 month low of $0.42 and a 12 month high of $2.05. The stock has a fifty day moving average price of $0.88 and a 200-day moving average price of $1.03.

Institutional Investors Weigh In On Adaptimmune Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC raised its holdings in shares of Adaptimmune Therapeutics by 130.4% in the third quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock worth $166,000 after buying an additional 98,581 shares during the last quarter. FMR LLC lifted its position in Adaptimmune Therapeutics by 3.0% during the 3rd quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock worth $1,655,000 after acquiring an additional 50,419 shares during the period. Baillie Gifford & Co. grew its stake in Adaptimmune Therapeutics by 10.7% during the 3rd quarter. Baillie Gifford & Co. now owns 16,775,860 shares of the biotechnology company’s stock valued at $15,944,000 after purchasing an additional 1,626,657 shares during the last quarter. GSA Capital Partners LLP purchased a new position in shares of Adaptimmune Therapeutics in the third quarter worth about $95,000. Finally, Fullcircle Wealth LLC acquired a new stake in shares of Adaptimmune Therapeutics during the third quarter worth about $33,000. Institutional investors and hedge funds own 31.37% of the company’s stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.